Influence of PI3K/AKT pathway on imatinib mesylate treatment outcome in chronic myeloid leukemia patients

被引：0
|
作者：
Banapuram, Swathi [1 ]
Gorre, Manjula [1 ]
Digumarti, Raghunadha Rao [2 ]
Satti, Vishnupriya [1 ]
Palle, Komaraiah [3 ]
Annamaneni, Sandhya [3 ,4 ]
机构：
[1] Osmania Univ, Hyderabad, Telangana, India
[2] Homi Bhabha Canc Hosp & Res Ctr, Visakhapatnam, Andhra Pradesh, India
[3] Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USA
[4] Osmania Univ, Dept Genet, Hyderabad, Telangana, India
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-4682
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4682
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Investigation of TSRP reverses imatinib resistance through the PI3K / Akt pathway in chronic myeloid leukemia
    He, Ying
    Ding, Jiyuan
    Liu, Liqin
    Chen, Jiajun
    Zhong, Hong
    Li, Changyu
    Xu, Xiaofeng
    ANNALS OF HEMATOLOGY, 2024, 103 (12) : 5285 - 5296
  • [2] Treatment of chronic myeloid leukemia with imatinib mesylate
    Ohno R.
    International Journal of Clinical Oncology, 2006, 11 (3) : 176 - 183
  • [3] Imatinib mesylate and treatment of chronic myeloid leukemia
    Yamada, Hisashi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2008, 106 : 39P - 39P
  • [4] Imatinib mesylate for the treatment of chronic myeloid leukemia
    Soverini, Simona
    Martinelli, Giovanni
    Lacobucci, Ilaria
    Baccarani, Michele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (06) : 853 - 864
  • [5] The PI3K/Akt/mTOR pathway:: a new therapeutic target in the treatment of acute myeloid leukemia
    Dos Santos, Cedric
    Recher, Christian
    Demur, Cecile
    Payrastre, Bernard
    BULLETIN DU CANCER, 2006, 93 (05) : 445 - 447
  • [6] Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation
    Merante, Serena
    Orlandi, Ester
    Bernasconi, Paolo
    Calatroni, Silvia
    Boni, Marina
    Lazzarino, Mario
    HAEMATOLOGICA, 2005, 90 (07) : 979 - 981
  • [7] Outcome of five patients with chronic myeloid leukemia after imatinib mesylate discontinuation
    Tothova, E.
    Kafkova, A.
    Surova, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 427 - 427
  • [8] Intermittent Imatinib Mesylate in Children with Chronic Myeloid Leukemia: Results and Outcome
    Malaspina, Francesco
    Putti, Maria Caterina
    Santopietro, Michelina
    Ladogana, Saverio
    Mura, Rosamaria
    Burnelli, Roberta
    Vacca, Nadia
    Rizzo, Lorenzo
    Moleti, Maria Luisa
    Testi, Anna Maria
    Biondi, Andrea
    Locatelli, Franco
    Saglio, Giuseppe
    Foa, Robin
    Giona, Fiorina
    BLOOD, 2018, 132
  • [9] THE INFLUENCE OF AGE ON TREATMENT OUTCOME OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA RECEIVING FRONTLINE IMATINIB
    Cojbasic, I.
    Golubovic, L. Macukanovic
    Vucic, M.
    Govedarovic, N.
    HAEMATOLOGICA, 2017, 102 : 736 - 737
  • [10] Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
    Alves, Alexandra Rodrigues
    Lima, William Gustavo
    Nagai, Michelly Martins
    Vilela Rodrigues, Joao Paulo
    Ayres, Lorena Rocha
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 52 (04) : 581 - 589
12345